Chen et al., 2024 - Google Patents
EGR3 Inhibits Tumor Progression by Inducing Schwann Cell‐Like DifferentiationChen et al., 2024
View PDF- Document ID
- 4294317384162386979
- Author
- Chen C
- Chen Y
- Li Y
- Zhang H
- Huang X
- Li Y
- Li Z
- Han J
- Wu X
- Liu H
- Sun T
- Publication year
- Publication venue
- Advanced Science
External Links
Snippet
The mechanism and function of the expression of Schwann characteristics by nevus cells in the mature zone of the dermis are unknown. Early growth response 3 (EGR3) induces Schwann cell‐like differentiation of melanoma cells by simulating the process of nevus …
- 101000896450 Homo sapiens Early growth response protein 3 0 title abstract description 140
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Haag et al. | H3. 3-K27M drives neural stem cell-specific gliomagenesis in a human iPSC-derived model | |
| Nie et al. | Breast phyllodes tumors recruit and repolarize tumor-associated macrophages via secreting CCL5 to promote malignant progression, which can be inhibited by CCR5 inhibition therapy | |
| Cai et al. | FOXP3+ macrophage represses acute ischemic stroke-induced neural inflammation | |
| Owen et al. | Prostate cancer cell‐intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone | |
| Baasch et al. | Cytomegalovirus subverts macrophage identity | |
| Huang et al. | Growth of Mycobacterium tuberculosis in vivo segregates with host macrophage metabolism and ontogeny | |
| Hanna et al. | Inhibition of Hedgehog signaling reprograms the dysfunctional immune microenvironment in breast cancer | |
| Wu et al. | YAP silencing by RB1 mutation is essential for small-cell lung cancer metastasis | |
| Huang et al. | Recent advances in understanding cancer-associated fibroblasts in pancreatic cancer | |
| Xu et al. | ZNF397 deficiency triggers TET2-driven lineage plasticity and AR-targeted therapy resistance in prostate cancer | |
| Chen et al. | EGR3 Inhibits Tumor Progression by Inducing Schwann Cell‐Like Differentiation | |
| Pozzi et al. | MCP-1/CCR2 axis inhibition sensitizes the brain microenvironment against melanoma brain metastasis progression | |
| Wang et al. | Disruption of Super‐Enhancers in Activated Pancreatic Stellate Cells Facilitates Chemotherapy and Immunotherapy in Pancreatic Cancer | |
| Xiang et al. | A ubiquitin‐dependent switch on MEF2D senses pro‐metastatic niche signals to facilitate intrahepatic metastasis of liver cancer | |
| Wang et al. | Fimepinostat Impairs NFκB and PI3K/AKT Signaling and Enhances Gemcitabine Efficacy in H3. 3K27M-Diffuse Intrinsic Pontine Glioma | |
| CN111073979A (en) | Gastric cancer therapy by blocking the CCL28 chemotactic pathway | |
| Li et al. | Oncolytic vaccinia virus armed with anti-CD47 nanobody elicit potent antitumor effects on multiple tumor models via enhancing innate and adoptive immunity | |
| CN111526894B (en) | Pharmaceutical composition for preventing or treating lung metastasis of cancer using a CHI3L1 inhibitor as an active ingredient | |
| KR20160061423A (en) | Perforin-2 activators and inhibitors as drug targets for infectious disease and gut inflammation | |
| WO2020073594A1 (en) | Application of amphiregulin in production of cell senescence and tumor diagnosis or regulation preparation | |
| WO2019074915A1 (en) | Netrin g1 as a biomarker for enhancing tumor treatment efficacy | |
| WO2021217556A1 (en) | Method for constructing model of vitiligo and the use of the model | |
| Izzo et al. | KLF4 promotes a KRT13+ hillock-like state in squamous lung cancer | |
| WO2024103313A1 (en) | Cancer therapy based on targeting irg1 | |
| EP3635098B1 (en) | T-cells modified to overexpress phf19 |